5[1]Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulatesystem [J]. AdvDrug Del Rev, 2001,47:55-64.
6[2]Jacobs C, Kayser O, Müller R H. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide [J]. Int J Pharm, 2000,196:161-164.
7[3]Liversidege G C, Cundy K C . Particle size reduction for im provement of oral bioavailability of hydrophobic drugs. I. Absolute oral bioavailability of nanocrystalline danazole in beagle dogs [J]. Int JPharm, 1995,127:91-97.
8[4]Duchene D, Ponchel G. Bioadhesion of solid oral dosage forms, why and how [J]. Eur J Pharm Biopharm, 1997,44:15-23.
9[5]Pimienta C, Chouinard F, Labib A, et al. Effects of various poloxamer coatings on in vitro adhesion of isohexylcyanoacrylate nanospheres to rat ileal segments under liquid flow [J]. Int J Pharm, 1992,80:1-8.
10[6]Takeuchi H, Yamamoto H, Niwa T, et al. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes [J]. Pharm Res, 1996,13:896-901.
